Nxera Pharma Co., Ltd. announced that it has achieved a development milestone under its multi-target collaboration and license agreement with Eli Lilly and Co. (LLY) targeting diabetes and metabolic diseases, resulting in a payment to Nxera. The payment amount is undisclosed under the agreement with Lilly. Nxera expects to receive the milestone payment in the third quarter of the fiscal year ending December 2025.
Nxera and Lilly entered the multi-target collaboration in 2022 to leverage Nxeras GPCR-focused structure-based drug design capabilities and Lilly's extensive development, commercialization and therapeutic area expertise. Lilly will now be responsible for further development and commercialization.
As per the terms of the agreement, Nxera is eligible to receive development and commercial milestones totalling up to US$694 million, plus tiered royalties on global sales.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.